.png)
Stage (next event)
Next Event
Expected Date
Phase 1
Data readout
TBA
Phase 1 trial continues; Update expected by year end
Catalyst Info & Data Links
MORE INFORMATION:
Phase 1 trial continues; Update expected by year end
Clinical data from its Phase 1 dose escalation study of MCLA-158 will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Symposium (ASCO GI) annual meeting being held virtually from January 15-17, 2021.
DRUG HISTORY:
Mechanism of Action
MCLA-158 is an antibody-dependent cell-mediated cytotoxicity (ADCC)-enhanced Biclonics® for the treatment of solid tumors, including the potential treatment of colorectal cancer, that binds to cancer stem cells expressing leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5) and epidermal growth factor receptor (EGFR). MCLA-158 is designed to use two different mechanisms of action. The first blocks growth and survival pathways in cancer stem cells. The second involves the recruitment and enhancement of immune effector cells to directly kill cancer stem cells that persist in solid tumors and cause relapse and metastasis.
JM (HC)
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
Recent Posts
See what the community is saying - click to see full post